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Fibroblast growth Factor 21-null 
Mice Do not exhibit an impaired 
response to Fasting
Patrick Joseph Antonellis, Meghan Patricia Hayes and Andrew Charles Adams*
Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN, USA
Fibroblast growth factor 21 (FGF21) is a pleotropic metabolic regulator, expression of 
which is elevated during fasting. To this end, the precise role played by FGF21 in the biol-
ogy of fasting has been the subject of several recent studies, which have demonstrated 
contributions to the regulation of both lipid and carbohydrate metabolism. In the present 
study, we compared wild-type (WT) and FGF21-null (FGF21KO) mice, demonstrating 
that, despite the significant induction of FGF21 during fasting in the WT animals, our 
strain of FGF21-null mice exhibits only limited impairments in their adaptation to nutrient 
deprivation. Specifically, fasted FGF21KO mice display a mild attenuation of glucone-
ogenic transcriptional induction in the liver accompanied by partially blunted glucose 
production in response to a pyruvate challenge. Furthermore, FGF21KO mice displayed 
only minor impairments in lipid metabolism in the fasted state, limited to accumulation 
of hepatic triglycerides and a reduction in expression of genes associated with fatty acid 
oxidation. To address the possibility of compensation to germline deletion of FGF21, we 
further interrogated the role of endogenous FGF21 via acute pharmacological block-
ade of FGF21 signaling. At the transcriptional level, we show that FGF21 signaling is 
required for full induction of gluconeogenic and oxidative genes in the liver. However, 
corroborating our findings in FGF21KO mice, pharmacological blockade of the FGF21 
axis did not profoundly disrupt the physiological response to fasting. Taken as a whole, 
these data demonstrate that, while FGF21 is partially required for appropriate gene 
expression during the fed to fasted transition, its absence does not significantly impact 
the downstream physiology of the fasted state.
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inTrODUcTiOn
Fibroblast growth factor 21 (FGF21) is a member of the endocrine subgroup of the FGF family, 
comprised of FGF19 (FGF15 in mice), FGF21, and FGF23. Unlike the canonical FGFs, members of 
this family lack a heparin-binding domain, which allows them to enter the circulation (1). Recently, 
it was demonstrated, through tissue-specific deletion, that the primary source of circulating FGF21 
is the liver (2). The systemic physiological effects of FGF21 are mediated by its binding to a recep-
tor complex composed of FGF receptor 1 (FGFR1) and the cofactor protein β-klotho (KLB) (3). 
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While FGFR1 is broadly distributed, KLB is mainly expressed in 
metabolically active tissues, such as liver, adipose, and pancreas. 
Thus, it is the expression of KLB, not FGFR1, which restricts the 
tissues FGF21 can act upon (4, 5).
Acute FGF21 administration in mice leads to activation of the 
FGF signaling pathway in both liver and adipose (6). However, 
deletion of FGFR1 or KLB, specifically in adipose, demonstrates 
that adipose tissue activation is intrinsically required for FGF21’s 
pharmacological effects (7, 8). In addition to these peripheral 
sites of action, it has recently been proposed that FGF21 may act 
centrally (9). Concordant with this assertion, expression of KLB 
has been reported in discrete areas of the hypothalamus, deletion 
of which has been reported to abrogate the metabolic effects of 
exogenous FGF21 administration (10). It has also been demon-
strated that central FGF21 activates the sympathetic nervous 
system and that intact sympathetic tone is required to mediate its 
effects at the periphery (11, 12).
In the liver, FGF21 expression primarily resides downstream 
of the transcription factor, peroxisome proliferator-activated 
receptor alpha (PPARα) (13). PPARα and, subsequently, FGF21 
are induced in states that demand enhanced hepatic lipid 
oxidation, such as fasting and ketogenic diet feeding (14, 15). 
Interestingly, FGF21-null (FGF21KO) mice have previously been 
reported to exhibit impairments in glucose and lipid metabolism 
(16). Furthermore, in response to feeding of a ketogenic diet, 
both global deletion and liver-specific FGF21 knockdown lead 
to hepatic triglyceride accumulation, accompanied by an attenu-
ation of hepatic oxidative gene expression (14, 17). In addition to 
defects in lipid metabolism, FGF21KO mice also exhibit enhanced 
adipose mass coupled with the development of larger adipocytes 
(17–19). Conversely, FGF21 transgenic mice (FGF21Tg) are 
leaner than their WT counterparts, with a concomitant increase 
in hepatic fatty acid oxidation (15, 16). In agreement with the 
phenotype of FGF21Tg animals, pharmacologic treatment with 
FGF21 leads to a significant decrease in body mass in preclinical 
models (20, 21). This reduction in body mass is primarily due 
to decreased adipose mass, thought to be driven in large part by 
significantly increased energy expenditure and a reduction in 
respiratory exchange ratio (RER), which when taken together are 
suggestive of a state of elevated lipid oxidation (20).
In the present study, we utilize both genetic and pharma-
cological approaches to assess the physiological role of FGF21 
during fasting. We demonstrate that, while our own strain of 
FGF21KO mice do exhibit impairments in the transcriptional 
regulation of pathways involved in lipid and carbohydrate 
metabolism during fasting, these defects had little in the way 
of physiological consequences. To further interrogate the 
physiological role of FGF21 during fasting and to address the 
potential for confounding developmental compensation in 
the FGF21KO mice, we sought to directly inhibit endogenous 
FGF21 signaling. To do so, we utilized a variant of the wild-
type human FGF21 protein lacking 17 N-terminal amino acid 
residues, termed ΔN17, which we have previously shown blocks 
FGF21 action in vivo (22). In agreement with the effects observed 
in FGF21KO mice, we found that treatment with ΔN17 either 
during the early fed to fasted transition or after a prolonged 
fast did significantly impact the transcriptional response, yet 
led to only minor physiological effects. Taken as a whole, these 
studies demonstrate that, while manipulation of the FGF21 axis 
can modify the transcriptional response to caloric deprivation, 
FGF21 is not explicitly required for an appropriate, integrated, 
physiological response to fasting.
MaTerials anD MeThODs
Proteins
Human FGF21ΔN17 was generated as previously described (23).
animals
All animals were individually housed in a temperature-controlled 
(24°C) facility with 12 h/12 h light/dark cycle. Animal protocols 
in this study were approved by the Eli Lilly and Co., Animal Use 
and Care Committee (Protocol No. 13-030).
comparison of WT and FgF21KO animals 
in the Fed and Fasted states
Male C57Bl/6J and FGF21 knockout (FGF21KO) mice (Taconic 
Farms) were maintained on a standard chow diet consisting of 
13% fat, 67% carbohydrate, and 20% protein caloric content 
(2014; Harlan Teklad, Madison, WI, USA) and had free access 
to food and water before randomization by weight. A cohort of 
mice from each genotype had their food removed at the begin-
ning of the light cycle and were sacrificed following a 24 h fast. 
A separate cohort from each genotype was allowed ad  libitum 
access to food and sacrificed at the end of the dark cycle. Prior 
to sacrifice, blood glucose levels were assessed using handheld 
glucometers (Accu-Chek Aviva; Roche Diagnostics, Indianapolis, 
IN, USA). Following sacrifice, liver and epididymal white adipose 
tissue (WAT) samples were rapidly dissected and flash frozen 
in liquid nitrogen. Whole blood was collected in EDTA coated 
tubes, centrifuged, and plasma collected for analysis. Each cohort 
consisted of at least six mice.
acute Treatment of WT animals
Male C57Bl/6J mice (Taconic Farms) 11–12 weeks of age were 
maintained on a standard chow diet (2014; Harlan Teklad). At 
the beginning of the light cycle, mice had their food removed and 
dosed with either 5 mg/kg of ΔN17 or vehicle via intraperitoneal 
(IP) injection. Number of injections and duration of study were 
as indicated. At the indicated time points, blood glucose was 
measured using handheld glucometers (Accu-Chek Aviva; Roche 
Diagnostics). At the end of each study, mice were sacrificed, and 
liver and WAT samples were rapidly dissected and flash frozen 
in liquid nitrogen. Whole blood was collected in EDTA-coated 
tubes, centrifuged, and plasma removed for analysis. Six mice 
were used for each treatment group.
Pyruvate Tolerance Test
Mice were fasted for the indicated amount of time. Following 
the fast, animals were administered 2 g/kg sodium pyruvate via 
IP injection. Blood glucose was measured at the indicated time 
points using handheld glucometers (Accu-Chek Aviva; Roche 
Diagnostics).
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Metabolites and hormones
Plasma triglycerides and free fatty acids were measured using a 
Hitachi 912 Clinical Chemistry analyzer (Roche Diagnostics). 
To  measure liver triglyceride content, a 10% tissue homogen-
ate was prepared and analyzed using a Hitachi 912 Clinical 
Chemistry analyzer. Circulating levels of insulin (Ultra Sensitive 
Mouse Insulin ELISA; CrystalChem, Downers Grove, IL, 
USA) and FGF21 (Mouse/Rat FGF21 Quantikine ELISA; R&D 
Systems, Minneapolis, MN, USA) were determined by ELISA 
assay. Colorimetric assays were used to determine plasma βHB 
(β-hydroxybutyrate LiquiColor; Stanbio Laboratories, Boerne, 
TX, USA) and liver glycogen content (Glycogen Assay Kit; 
Sigma-Aldrich, St. Louis, MO, USA).
Protein Measurements
Protein was extracted from tissue using mammalian protein 
extraction reagent (M-PER) (Pierce, Rockford, IL, USA) contain-
ing 1× halt protease and phosphatase inhibitor cocktail (Pierce). 
FGF21 protein concentration was determined by ELISA (Mouse/
Rat FGF21 Quantikine ELISA; R&D Systems). The average 
minimum detectable dose of the assay is 3.81  pg/mL, and all 
samples measured fell within the linear range of 31.3–2000 pg/
mL. Total and phosphorylated hormone-sensitive lipase (HSL) 
was determined by Western blot. Briefly, WAT protein extracts 
were separated by SDS-PAGE and transferred to nitrocellulose 
membranes, which were probed using anti-rabbit antibodies 
to total and phosphorylated HSL (Cell Signaling Technologies, 
Danvers, MA, USA).
rna isolation, rT, and real-time 
Quantitative Pcr
RNA was isolated from tissues using TRIzol reagent (Invitrogen, 
Carlsbad, CA, USA) and the RNeasy lipid mini kit (Qiagen, Venlo, 
Netherlands) and then reverse transcribed into cDNA using 
the Quantitect Reverse Transcription Kit (Qiagen). Reactions 
were performed on an Applied Biosystems QuantStudio 7 Real-
Time PCR System (Applied Biosystems, South San Francisco, 
CA, USA), CT values were normalized to β-actin, and relative 
expression was calculated by the ΔΔCT method. Fold change 
was calculated by normalizing relative expression to the proper 
control, WT-fed or PBS-treated animals. Assays-on-Demand 
Gene expression products (Applied Biosystems) were as follows: 
CPT1a Mm01231183-m1; ACADS Mm00431617_m1; ACADM 
Mm01323360_g1; ACADL Mm00599660_m1; ACADVL Mm00 
44293_m1; HADH Mm00492535_m1; CD36 Mm01135198_m1; 
G6PC Mm00839363-m1; PCK1 Mm01247058-m1; HMGCS2 
Mm00550050_m1; BDH1 Mm00558330_m1; PGC1α Mm01 
208835-m1; CIDEA Mm00432554_m1; UCP1 Mm01244861_m1; 
FASN Mm00662319_m1; HSL Mm00495359_m1; ATGL Mm00 
503040_m1; LPL Mm00434770_m1; and FGF21 Mm00840165_g1.
statistical analysis
Data are presented as mean ± SEM. Statistical analysis was per-
formed using two-way ANOVA or one-way ANOVA followed by 
Dunnett’s multiple comparisons test or T-test where appropriate. 
Differences were considered significant when P < 0.05.
resUlTs
FgF21KO Mice exhibit Modest alterations 
in lipid and carbohydrate Metabolism 
during a Fast
To assess the role of FGF21 during the adaptive response to fast-
ing, we compared cohorts of WT and FGF21KO mice in both 
the fed state and following a 24-h fast. We found that increased 
plasma levels of FGF21 during fasting (Figure 1A) correlated with 
a significant elevation in FGF21 mRNA (Figure 1B) and protein 
(Figure 1C) in the liver, but not adipose tissue (Figures 1B,C), 
consistent with recent findings (2). Both WT and FGF21KO ani-
mals exhibited expected reductions in blood glucose (Figure 1D) 
and insulin (Figure 1E). However, while FGF21KO animals did 
appear to have mildly reduced blood glucose levels compared 
to WT mice in the fasted state, this effect was not statistically 
significant (Figure 1D).
It has been demonstrated that FGF21 is important for the 
induction of ketosis when animals are maintained on a ketogenic 
diet (14, 16). However, consistent with previous studies (17), 
our strain of FGF21KO animals fed on a chow diet did not show 
impaired βHB production in the fasted state (Figure 1F). Nor were 
circulating triglycerides altered in either genotype (Figure 1G). 
Interestingly, plasma free fatty acids were elevated in fasted WT, 
but not FGF21KO animals (Figure 1H). Therefore, as FGF21 has 
been implicated in the regulation of lipolysis (18), we investigated 
whether altered lipase activity in the WAT of the FGF21KO animals 
was responsible for this discrepancy. We found no differences in 
the expression of HSL or lipoprotein lipase (LPL); however, while 
induction of adipose triglyceride lipase (ATGL) in the fasted state 
did not reach significance in FGF21KO mice, it did trend upward 
to a similar degree as observed in the WT animals (Figure 2B). 
Furthermore, during fasting, we observed equivalent phospho-
rylation of HSL in adipose tissue of WT and FGF21KO animals 
(Figure  2C). In addition to mediators of lipolysis, we assessed 
the known FGF21 target genes peroxisome proliferator-activated 
receptor gamma coactivator 1-alpha (PGC1α) and uncoupling 
protein 1 (UCP1) and found no differences in their expression 
between the genotypes (Figure 2B).
While both WT and FGF21KO mice exhibited elevated hepatic 
triglyceride content following a fast, FGF21KO animals accumu-
lated significantly more than their WT counterparts (Figure 1I). 
As we found no evidence of enhanced lipolysis in adipose tissue, 
we next examined the expression of genes associated with fatty acid 
import and oxidation in the liver. Importantly, we found that the 
induction of genes involved in fatty acid oxidation (carnitine pal-
mitoyltransferase 1A, CPT1a; acyl-Coenzyme A dehydrogenase, 
short chain, ACADs; acyl-Coenzyme A dehydrogenase, medium 
chain, ACADM; acyl-Coenzyme A dehydrogenase, long chain, 
ACADL; acyl-Coenzyme A dehydrogenase, very long chain, 
ACADVL) were attenuated in FGF21KO animals (Figure  2A). 
Additionally, FGF21KO animals exhibited a significantly greater 
increase in expression of the fatty acid transporter, CD36, in the 
fasted state (Figure 2A).
Next, we sought to determine the impact of global FGF21 dele-
tion on carbohydrate metabolism during fasting. We found that, 
while there was no difference in glucose-6-phosphatase (G6PC) 
FigUre 1 | FgF21 is primarily expressed in the liver and is dispensable for the physiological response to fasting. WT and FGF21KO animals were either 
allowed ad libidum access to food (fed) or subjected to a 24-h fast (fasted). (a) Plasma FGF21 levels were measured in WT animals. (B) FGF21 mRNA and (c) 
protein expression were measured in liver and adipose tissue from WT animals. (D) Blood glucose was assessed via glucometer in each cohort. Plasma was 
collected from WT and FGF21KO animals and used to determine circulating levels of (e) insulin, (F) βHB, (g) triglycerides, and (h) free fatty acids. The concentration 
of (i) triglycerides and (J) glycogen was measured in the livers of WT and FGF21KO animals. (K) A pyruvate tolerance test was performed on a separate cohort of 
WT and FGF21KO animals by administration of 2 g/kg sodium pyruvate following a 22-h fast. *p < 0.05 vs. fed; α, p < 0.05 vs. WT Fed; β, p < 0.05 vs. FGF21KO 
fed; φ, p < 0.05 vs. WT fasted; #, p < 0.05 vs. WT. No statistical difference was observed in fed measurements between genotypes.
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expression, induction of phosphoenolpyruvate carboxykinase 1 
(PCK1) during fasting was significantly attenuated in FGF21KO 
mice (Figure  2A). To assess whether the observed attenuation 
in PCK1 gene expression in FGF21KO mice impacted gluco-
neogenic capacity, we conducted a pyruvate tolerance test (PTT). 
To our surprise, we found that FGF21KO mice exhibited only a 
modest reduction in gluconeogenesis following a pyruvate chal-
lenge (Figure 1K). This minor effect on carbohydrate metabolism 
was reflected in maintenance of normal hepatic glycogen content 
in the FGF21KO animals (Figure 1J).
Pharmacological inhibition of endogenous 
FgF21 signaling has no effect on lipid 
and carbohydrate Utilization during the 
early Fed to Fasted Transition
To investigate the potential role of endogenous FGF21 during the 
transition from the fed to fasted state and to mitigate potential 
concerns regarding developmental compensation to germline 
deletion of FGF21, we subjected WT animals to a time course 
of FGF21–ΔN17 (ΔN17) treatment. Since ΔN17 functions as an 
antagonist of FGF21 action in vivo (22), pharmacological admin-
istration of the protein allows for acute blockade of the FGF21 
axis. At the beginning of the light cycle, animals had their food 
removed, then were dosed with ΔN17 every 3 h for 12 h. During 
this initial transition period, treatment with ΔN17 had no signifi-
cant effect on blood glucose (Figure 3A) or plasma insulin levels 
(Figure 3B). Additionally, there was no effect on circulating levels 
of βHB (Figure 3C), triglycerides (Figure 3D), free fatty acids 
(Figure 3E), hepatic triglyceride (Figure 3F), or liver glycogen 
content (Figure 3G). When gene expression was assessed in the 
liver, we found that of the genes involved in fatty acid oxidation 
(CPT1a, ACADS, ACADM, ACADVL, HADH), only HADH was 
significantly altered by ΔN17 treatment (Figure 3H). Similarly, 
genes related to gluconeogenesis (G6PC, PCK1) and ketone body 
production (3-hydroxybutyrate dehydrogenase, type 1, BDH1; 
FigUre 2 | Oxidative and gluconeogenic gene expression is attenuated in the liver, while lipase gene expression and activity in WaT remains 
unaltered in fasted FgF21KO mice. (a) In the liver, expressions of genes associated with fatty acid oxidation (CPT1a, ACADS, ACADM, ACADL, ACADVL, 
HADH), fatty acid import (CD36), gluconeogenesis (G6PC, PCK1), and ketone body production (HMGCS2, BDH1) were measured. (B) Expressions of genes 
associated with lipolysis (HSL, ATGL, LPL), fatty acid synthesis (FASN), fatty acid import (CD36), and thermogenesis (CIDEA, UCP1) were measured. In adipose 
tissue: α, p < 0.05 vs. WT Fed; β, p < 0.05 vs. FGF21KO fed; φ, p < 0.05 vs. WT fasted. No statistical differences were observed between genotypes in fed 
expression of any gene measured. (c) The amount of total and phosphorylated HSL was assessed by Western blot in WAT of WT and FGF21KO animals in both 
the fed and fasted state.
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3-hydroxy-3-methylglutaryl-CoA synthase 2, HMGCS2) were 
unaffected (Figure 3H). Somewhat surprisingly, in the WAT of 
animals treated with ΔN17, we did observe reduced expression 
of PGC1α (Figure 3I). These data lead us to conclude that endog-
enous FGF21 has a limited role during early fasting, supportive of 
earlier studies, which demonstrated that full induction of hepatic 
and serum FGF21 requires prolonged fasting (14, 15).
interruption of FgF21 signaling during 
Prolonged Fasting Does not significantly 
impact lipid or carbohydrate Metabolism
To assess the role of FGF21 in the regulation of gluconeogenesis 
during late fasting, WT animals were fasted for 21  h, given a 
single injection of ΔN17, and then subjected to a PTT. Consistent 
FigUre 3 | endogenous FgF21 is not required for proper lipid and carbohydrate metabolism during the fed to fasted transition. At the beginning of 
the light cycle, WT animals had their food removed and were administered 5 mg/kg ΔN17 once every 3 h for 12 h. (a) Blood glucose measurements were taken 
via glucometer at the specified time points. Circulating levels of (B) insulin, (c) βHB, (D) triglycerides, and (e) free fatty acids were determined from plasma 
samples collected at the end of the study. Liver samples were taken at the end of the study and used to determine the concentrations of (F) triglycerides and (g) 
glycogen. (h) In the liver, expression of FGF21 as well as genes associated with fatty acid oxidation (CPT1a, ACADS, ACADM, ACADL, ACADVL, HADH), fatty acid 
import (CD36), gluconeogenesis (G6PC, PCK1), and ketone body production (HMGCS2, BDH1) were measured. (i) Expression of FGF21 in addition to genes 
associated with lipolysis (HSL, ATGL, LPL), fatty acid synthesis (FASN), fatty acid import (CD36), and thermogenesis (CIDEA, UCP1) were measured in adipose 
tissue. *p < 0.05 vs. PBS.
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with our earlier studies in the FGF21KO mice, we found that 
ΔN17 treatment had no effect on gluconeogenesis following a 
pyruvate challenge (Figure  4A). To determine whether other 
discrete aspects of the fasted response were impacted by inhibi-
tion of FGF21 signaling, a separate cohort of 23-h fasted mice 
was treated with a single injection of ΔN17 and sacrificed 1  h 
later. In agreement with our previous findings, acute treatment 
with ΔN17 had no significant effect on circulating glucose 
(Figure 4B), insulin (Figure 4C), βHB (Figure 4D), or free fatty 
acid (Figure 4F) levels. Mice treated with ΔN17 had significantly 
elevated plasma triglycerides (Figure 4E); however, both hepatic 
triglyceride (Figure 4G) and glycogen (Figure 4H) content were 
unchanged by ΔN17 treatment. The gene expression profile in the 
ΔN17-treated animals exhibited trends reflective of the results 
observed in the FGF21KO mice; however, none of these differ-
ences reached statistical significance in the liver (Figure 4I) or 
adipose (Figure 4J), suggesting that chronic changes to FGF21 
tone may be required to observe the full magnitude of its effects.
FigUre 4 | Blockade of FgF21 signaling during late fasting does not impair the fasted response. WT mice were fasted for 21 h, administered 5 mg/kg 
ΔN17, and then subjected to a PTT 1 h later by administration of 2 g/kg sodium pyruvate. (a) Blood glucose was measured at the specified time points via 
glucometer. A separate cohort of WT mice was fasted for 23 h, administered 5 mg/kg ΔN17, and then sacrificed 1 h later. (B) Blood glucose was assessed via 
glucometer. Plasma samples were collected and used to determine circulating levels of (c) insulin, (D) βHB, (e) triglycerides, and (F) free fatty acids. Hepatic (g) 
Triglyceride and (h) glycogen content was measured. (i) In the liver, expression of FGF21 as well as genes associated with fatty acid oxidation (CPT1a, ACADS, 
ACADM, ACADL, ACADVL, HADH), fatty acid import (CD36), gluconeogenesis (G6PC, PCK1), and ketone body production (HMGCS2, BDH1) were measured. (J) 
Expression of FGF21 in addition to genes associated with lipolysis (HSL, ATGL, LPL), fatty acid synthesis (FASN), fatty acid import (CD36), and thermogenesis 
(CIDEA, UCP1) were measured in adipose tissue. *p < 0.05 vs. PBS.
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DiscUssiOn
Despite significant study, including the generation of three 
separate FGF21-null models (16–18), the physiological role of 
FGF21 remains uncertain. Broadly, it has been proposed that 
a primary role of FGF21 is to coordinate lipid and carbohy-
drate metabolism during nutrient deprivation. In support of 
this view, FGF21 has been shown to be induced by nutrient-
deficient states such as prolonged fasting as well as during 
exposure to ketogenic (17) and protein-deficient diets (24–26). 
In the present study, we investigated the role of FGF21 in the 
response to fasting through examination of our own strain of 
FGF21KO animals, in addition to pharmacological inhibition 
of endogenous FGF21 action.
Congruent with previously published findings (14), we show 
that, following a 24-h fast, plasma concentrations of FGF21 were 
indeed significantly elevated in WT mice. This increase in circu-
lating FGF21 corresponded with a significant elevation in FGF21 
mRNA and protein in the liver, but not adipose, supportive of 
a recent report describing the liver as the primary source of 
endocrine FGF21 (2). We went on to extend these findings by 
demonstrating that, while FGF21KO mice were able to maintain 
glycemia in a manner equivalent to their WT counterparts, they 
did exhibit defects in lipid metabolism during fasting. The eleva-
tion of circulating free fatty acids in the fasted state observed 
in WT mice was abolished in FGF21KO animals despite both 
genotypes having similar HSL abundance and activity in WAT. 
Interestingly, in addition to reduced serum FFA levels, the 
FGF21-null animals also exhibited elevated hepatic triglyceride 
accumulation in the fasted state. When hepatic gene expression 
was assessed, we found attenuation in the induction of genes 
involved in fatty acid oxidation as well as increased expression 
of the fatty acid transporter, CD36. Therefore, we suggest that 
reduced oxidative capacity coupled with increased fatty acid 
import in the liver may serve to explain both the attenuation of 
free fatty acids in circulation and the increased hepatic triglyc-
eride content observed in FGF21KO mice during fasting condi-
tions. In support of this conclusion, it has been demonstrated that 
hepatic CD36 correlates with dyslipidemia in diet-induced obese 
animals; furthermore, overexpression of CD36 in the liver leads 
to increased fatty acid uptake and triglyceride storage in the liver 
(27). It has also been shown that reducing fatty acid oxidation 
through the use of a specific inhibitor of liver CPT1 causes hepatic 
triglyceride accumulation (28). Thus, the coupling of these two 
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mechanisms would serve as a mechanistic basis for the impaired 
lipid homeostasis observed in our strain of FGF21KO mice.
The primary manner in which FGF21 is thought to regulate 
glucose metabolism is via modulation of hepatic gluconeogenesis 
(29). In support of this contention, FGF21-null animals have 
been reported to exhibit attenuated hepatic gluconeogenic gene 
expression in the fasted state (16). Furthermore, it has also been 
shown that this transcriptional defect translates to a functional 
impairment in gluconeogenesis following a fast (30). However, 
here, we show that despite attenuation in gluconeogenic gene 
expression in the liver, our own strain of FGF21KO animals had 
no significant impairment of gluconeogenesis, exhibiting nearly 
identical endogenous glucose production as WT mice. These 
results are in agreement with the phenotype reported in a third 
strain of FGF21KO mice (31).
Given the discordance between the three strains of FGF21KO 
mice and to avoid potential confounding effects of compensation 
due to germline deletion, we further interrogated the role of the 
FGF21 axis in the fasted state, pharmacologically. Specifically, we 
inhibited endogenous FGF21 through the use of a truncated form 
of the protein (ΔN17) during both the early and late phases of 
the fed to fasted transition. Treatment with ΔN17 had little effect 
on early fasting, which given the short nature of the fast (12 h) 
and that animals would not normally be eating much during this 
time, is not wholly unexpected. However, in 24-h-fasted animals, 
we found that interruption of FGF21 signaling led to little more 
than a blunting of the transcriptional response to fasting. Indeed, 
in spite of a diminished transcriptional response, ΔN17 treat-
ment had no effect on hepatic gluconeogenesis in response to 
a pyruvate challenge nor did it significantly alter systemic lipid 
homeostasis. These results were reminiscent of the physiological 
effects observed in two of the three strains of FGF21KO mice; 
however, they did not fully recapitulate the phenotype observed 
in those animals. It is possible that transcriptional changes 
during later stages of fasting are required for FGF21 to exert its 
physiological effects; therefore, longer duration of ΔN17 cover-
age would be required. Alternatively, the nature of endogenous 
FGF21 action may exist not under the conditions of prolonged 
fasting, but instead become manifest in a state of true starvation. 
Thus, longer periods of nutrient deprivation (>24 h) followed by 
ΔN17 administration may illuminate the biological processes 
under the control of elevated FGF21 during fasting.
While it appears that FGF21 is required for a full transcriptional 
response to fasting, the physiological consequences of its loss are 
extremely limited in nature. Furthermore, those physiological dif-
ferences we did observe were related specifically to the uptake and 
subsequent oxidation of hepatic lipids. Taken as a whole, these 
findings support the view that FGF21 does not play a meaningful 
role in the mobilization of energy stores during nutrient depriva-
tion, but, instead, acts in an autocrine manner in the fasted state 
to facilitate hepatic lipid homeostasis. We suggest that, given that 
the transcriptional changes are consistent in all three lines of 
FGF21KO mice, the range of physiological responses observed 
may be due to the environment in which the mice are housed or 
the variance in the specific experimental conditions of the studies.
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